Epirubicin glucuronidation and UGT2B7 developmental expression

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 2097-2101

  Zaya, Matthew J ^a   Hines, Ronald N ^a   Stevens, Jeffrey C ^b  

^a PFIZER INC   (United States)

^b Children's Hospital and Health System ^*

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; GLYCOSYLTRANSFERASE; UGT 2B7 PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; INFANT; LIVER MICROSOME; NEWBORN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; EPIRUBICIN; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; MICROSOMES, LIVER;

EID: 33751540127     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011387     Document Type: Article

References (28)

1. Anderson BJ, McKee AD, and Holford NH (1997) Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 33:313-327.
2. Barker IK, Crawford SM, and Fell AF (1996) Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy. J Chromatogr B Biomed Appl 681:323-329.
3. Choonara IA, McKay P, Hain R, and Rane A (1989) Morphine metabolism in children. Br J Clin Pharmacol 28:599-604.
4. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
5. de Wildt SN, Kearns GL, Leeder JS, and van den Anker JN (1999) Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439-452.
6. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
7. Harris NM, Anderson WR, Lwaleed BA, Cooper AJ, Birch BR, and Solomon LZ (2003) Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma. Cancer 97:71-78.
8. Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329-332.
9. Hollander M and Wolfe DA (1999) Nonparametric Statistical Methods. John Wiley & Sons, New York.
10. Ikushiro S, Emi Y, and Iyanagi T (1997) Protein-protein interactions between UDPglucuronosyltransferase isozymes in rat hepatic microsomes. Biochemistry 36:7154-7161.
11. Innocenti F, Iyer L, Ramirez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
12. Ishii Y, Miyoshi A, Watanabe R, Tsuruda K, Tsuda M, Yamaguchi-Nagamatsu Y, Yoshisue K, Tanaka M, Maji D, Ohgiya S, et al. (2001) Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation. Mol Pharmacol 60:1040-1048.
13. Kalvass JC, Tess DA, Giragossian C, Linhares MC, and Maurer TS (2001) Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 29:1332-1336.
14. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, et al. (2003) Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97:2006-2012.
15. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236-243.
16. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, and Voute PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819-829.
17. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (Lond) 227:680-685.
18. Launchbury AP and Habboubi N (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19:197-228.
19. Lunardi G, Venturini M, Vannozzi MO, Tolino G, Del ML, Bighin C, Schettini G, and Esposito M (2002) Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. Ann Oncol 13:280-285.
20. Meech R and Mackenzie PI (1997) UDP-glucuronosyltransferase, the role of the amino terminus in dimerization. J Biol Chem 272:26913-26917.
21. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
22. Ormrod D, Holm K, Goa K, and Spencer C (1999) Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 15:389-416.
23. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:48-57.
24. Remmel RP and Burchell B (1993) Validation and use of cloned, expressed human drugmetabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46:559-566.
25. Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45 (Suppl 2):20-30.
26. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
27. Weenen H, Lankelma J, Penders PG, McVie JG, ten Bokkel Huinink WW, de Planque MM, and Pinedo HM (1983) Pharmacokinetics of 4′-epi-doxorubicin in man. Investig New Drugs 1:59-64.
28. Weenen H, van Maanen JM, de Planque MM, McVie JG, and Pinedo HM (1984) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin. Eur J Cancer Clin Oncol 20:919-926.